Compare Amphastar Pharmaceuticals Inc (AMPH) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Lumen Technologies Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Lumen Technologies Inc trades at $6.72 (market cap $6.93B). The key difference: Lumen Technologies Inc is far larger — about 8.4× Amphastar Pharmaceuticals Inc's market cap, and Lumen Technologies Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | LUMN | |
|---|---|---|
Market Cap | $826.08M | $6.93B |
Sector | Health | Media |
52-Week High | $30.81 | $11.83 |
52-Week Low | $16.87 | $3.70 |
Enterprise Value | $1.22B | $18.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
LUMN trades at $6.73, down 0.3% on the day, with a bearish technical signal but oversold RSI readings. The company reported a net loss of -$1.74B for 2025, though revenue remains substantial at $12.40B. Recent news highlights the acquisition of Alkira to bolster AI-era networking capabilities and cost-saving initiatives targeting $1B annually by 2027. Debt levels are high at $17.49B long-term, but leverage is trending downward.
The outlook is mixed: positive catalysts include strategic acquisitions and cost reductions, but persistent losses and high debt pose significant risks. Analyst consensus is cautious with a Hold rating predominating, though the $8.25 price target suggests modest upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
